Regulus Therapeutics (RGLS) Competitors $1.38 -0.02 (-1.43%) (As of 09:35 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RGLS vs. ALIM, CDXS, XOMA, VNDA, LXRX, VSTM, ACHV, AGEN, FBIO, and SABSShould you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Alimera Sciences (ALIM), Codexis (CDXS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Achieve Life Sciences (ACHV), Agenus (AGEN), Fortress Biotech (FBIO), and SAB Biotherapeutics (SABS). These companies are all part of the "medical" sector. Regulus Therapeutics vs. Alimera Sciences Codexis XOMA Vanda Pharmaceuticals Lexicon Pharmaceuticals Verastem Achieve Life Sciences Agenus Fortress Biotech SAB Biotherapeutics Regulus Therapeutics (NASDAQ:RGLS) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability. Does the MarketBeat Community prefer RGLS or ALIM? Regulus Therapeutics received 134 more outperform votes than Alimera Sciences when rated by MarketBeat users. Likewise, 63.80% of users gave Regulus Therapeutics an outperform vote while only 55.80% of users gave Alimera Sciences an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes49063.80% Underperform Votes27836.20% Alimera SciencesOutperform Votes35655.80% Underperform Votes28244.20% Which has better earnings & valuation, RGLS or ALIM? Alimera Sciences has higher revenue and earnings than Regulus Therapeutics. Alimera Sciences is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$1.07-1.29Alimera Sciences$99.68M2.91-$20.13M-$1.57-3.53 Which has more risk and volatility, RGLS or ALIM? Regulus Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Do institutionals & insiders have more ownership in RGLS or ALIM? 92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is RGLS or ALIM more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -14.74%. Alimera Sciences' return on equity of -33.70% beat Regulus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -53.07% -48.58% Alimera Sciences -14.74%-33.70%-9.63% Do analysts rate RGLS or ALIM? Regulus Therapeutics currently has a consensus price target of $10.80, indicating a potential upside of 682.61%. Alimera Sciences has a consensus price target of $8.00, indicating a potential upside of 44.40%. Given Regulus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regulus Therapeutics is more favorable than Alimera Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Alimera Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer RGLS or ALIM? In the previous week, Regulus Therapeutics had 5 more articles in the media than Alimera Sciences. MarketBeat recorded 5 mentions for Regulus Therapeutics and 0 mentions for Alimera Sciences. Alimera Sciences' average media sentiment score of 0.00 beat Regulus Therapeutics' score of -0.30 indicating that Alimera Sciences is being referred to more favorably in the news media. Company Overall Sentiment Regulus Therapeutics Neutral Alimera Sciences Neutral SummaryRegulus Therapeutics beats Alimera Sciences on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGLS vs. The Competition Export to ExcelMetricRegulus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.39M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.294.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book1.0410.216.946.30Net Income-$30.04M$153.61M$119.12M$225.93M7 Day Performance-8.00%-2.00%-1.84%-1.32%1 Month Performance-8.00%-7.47%-3.65%0.60%1 Year Performance0.73%31.80%31.64%26.23% Regulus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGLSRegulus Therapeutics2.4586 of 5 stars$1.38-1.4%$10.80+682.6%+0.0%$90.39MN/A-1.2930ALIMAlimera SciencesN/A$5.54flat$8.00+44.4%N/A$290.24M$99.68M-3.53150CDXSCodexis4.1969 of 5 stars$4.43+2.3%$8.33+88.1%+117.6%$360.51M$70.14M0.00250XOMAXOMA4.308 of 5 stars$30.02-0.3%$78.50+161.5%+96.6%$353.64M$4.76M0.0010Positive NewsVNDAVanda Pharmaceuticals4.4326 of 5 stars$4.88-0.4%$15.50+217.6%+36.9%$284.55M$192.64M-17.50203LXRXLexicon Pharmaceuticals1.9366 of 5 stars$0.81+0.3%$6.00+640.6%-31.6%$199.48M$1.20M0.00285Analyst RevisionVSTMVerastem2.7428 of 5 stars$3.82+0.8%$12.50+227.2%-41.2%$170.03M$2.60M-1.1950Analyst DowngradeAnalyst RevisionNews CoverageACHVAchieve Life Sciences1.4887 of 5 stars$4.23-1.6%$14.80+249.9%-21.9%$145.47MN/A0.0020AGENAgenus3.8851 of 5 stars$2.62-1.9%$10.00+281.7%-82.0%$61.47M$156.31M0.00389Analyst RevisionFBIOFortress Biotech3.0653 of 5 stars$1.58+0.3%$13.67+767.7%-43.9%$43.47M$84.51M0.00186Analyst ForecastAnalyst RevisionSABSSAB Biotherapeutics3.5154 of 5 stars$3.06-5.6%$12.40+305.2%+267.0%$28.24M$2.24M0.00140 Related Companies and Tools Related Companies Alimera Sciences Alternatives Codexis Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Lexicon Pharmaceuticals Alternatives Verastem Alternatives Achieve Life Sciences Alternatives Agenus Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RGLS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts